|
| ||||
|
1日目 | 2日目 | RNA干渉（RNAi）は、潜在的薬剤標的の特定とバリデーション、未知の細胞経路の探求、および全ゲノム機能的スクリーン実施のためのスクリーニングツールとして広く用いられています。このスクリーンは、低分子干渉RNA（siRNA）と短ヘアピンRNA（shRNA）を用いて開発され、現在はかなり堅牢かつ感受性が高いものであり、信頼性が高く高処理なものとなっています。この会議は、様々に応用される体外および体内RNAiスクリーンの活用、適切なモデルシステムと試薬の選択、RNAiデリバリー、オフターゲット効果、偽陽性および陰性などの解決、品質管理とデータ分析の改善などについて話し合うイベントです。 11月3日（木）
アッセイデザインと設定 1:30 pm Chairperson’s Remarks Christophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience GmbH 1:40 Talk Title to be Announced Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research 2:10 Screening Approaches Towards Identifying Genes Associated with DNA Re-Replication in Cancer Cells Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, NIH The NIH Chemical Genomics Center has established an RNAi screening facility that performs screens in collaboration with investigators throughout the NIH intramural community. An initial genome-wide campaign involved screening for genes associated with aberrant DNA replication. Screening was conducted using libraries comprised of both pooled and individual siRNAs. Combining these approaches led to a thorough examination of genes associated with DNA replication and served as a way to compare the value of both platforms. 2:40 RNAi Screening Comes of Age: For the Love of My Target Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center RNAi screening has offered the premise of performing several thousand simultaneous knockdowns leading to the discovery and validation of existing and novel targets. Several years on, has the technology matured enough to keep up with its premise? 3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing 3:45 Speaker to be Announced
5:45 End of Day
1日目 | 2日目 | |
|
|||
|
|
||||
